tbuckley/cabot-search huggingface dataset:
Interaction between GSTM1/GSTT1 Polymorphism and Blood Mercury on Birth Weight
Authors: Bo-Eun Lee, Yun-Chul Hong, Hyesook Park, Mina Ha, Bon Sang Koo, Namsoo Chang, Young-Man Roh, Boong-Nyun Kim, Young-Ju Kim, Byung-Mi Kim, Seong-Joon Jo, Eun-Hee Ha
Journal: Environmental Health Perspectives (2009)
Sarcoidosis
Authors: Lloyd S. Ralston
Journal: JAMA (1968)

In this readable, well organized, beautifully illustrated, excellent volume, the author has gone about his task in the best tradition of fine British medical writers. He says what he has to say with beautiful clarity and amazing brevity. He covers the field and then he stops! How one wishes this talent could be put into a vaccine and given liberally to many American colleagues who dilute their published "pearls" in a discouraging mass of pure paperweight. In 27 chapters, Dr. Scadding, with the sure touch of an expert, takes us from historical survey through treatment. Much of the latter, however, is covered throughout the main body of the text where appropriate special manifestations in organs and systems are considered in detail. The author brings over 25 years experience to the writing of this volume, but his personal observations and views are correlated with the published experience of others and those
National Cancer Institute (NCI) Cancer Prevention Fellowship Program (CPFP)
Journal: JNCI Journal of the National Cancer Institute (1987)

National Cancer Institute (NCI) Cancer Prevention Fellowship Program (CPFP) Get access JNCI: Journal of the National Cancer Institute, Volume 79, Issue 3, September 1987, Page 610, https://doi.org/10.1093/jnci/79.3.610-a Published: 01 September 1987
Sleeping pills.
Authors: M R Bond, I B Pearson, C P Seager
Journal: BMJ (1970)

toin (D.P.H.) and of reduced levels of serum and C.S.F.folate.In weanling rats placed on a folate-deficient diet profound falls of serum and tissue folate were observed, in contrast to cerebral folate con- centrations which were maintained within the normal range.A similar reduction in serum and tissue folate concentrations was demonstrated in rats administered toxic doses of D.P.H. daily for up to 120 days together with a folate deficient diet; in the presence of substantial serum and tissue concentrations of D.P.H., no significant change in cerebral folate levels was observed.Tissue folate and D.P.H. concentrations were determined in cats rendered ataxic by the daily oral administration of D.P.H. for one to four weeks.In the presence of moderate depression of the serum, tissue, and C.S.F.folate concentrations, only minor changes were demonstrated in regional cerebral folate activity.Cats receiving D.P.H. together with folic acid supplements also exhibited ataxia in the presence of substantial increases in serum tissue and C.S.
An esophageal electrode for recording arrhythmias
Authors: S. I. Cohen
Journal: JAMA (1967)

<h3>To the Editor:—</h3> Identification of atrial activity is essential to the accurate electrocardiographic diagnosis of basic rhythm disturbances. When atrial activity is obscured by a rapid ventricular rate, right-sided precordial leads or esophageal leads should always be obtained.<sup>1</sup>Often the latter method is the most rewarding because of the proximity of the esophagus to the left atrium. Simple esophageal recording electrodes have been modified to increase the definition of atrial activity. Innovations have included bipolar and tripolar electrodes with a salt bridge<sup>2</sup>and the inclusion of many recording points along the electrode. These improved electrodes were made to individual specifications and not employed by the general medical community. Transvenous pacemakers have been utilized since 1959 for the management of Adams-Stokes attacks and heart-block. These pacemakers are manufactured in unipolar, bipolar, or tripolar models, any one of which can be employed as an esophageal electrode in the usual manner.
Table of Contents
Authors: Terumi Kobayashi, Taku Inokuchi, Asako Yamamoto, Sumio Takahashi, Tuneyoshi Ka, Zenta Tsutsumi, Hiroki Saito, Yuji Moriwaki, Tetsuya Yamamoto, Amy Halverstadt, Dana Phares, Kenneth Wilund, Andrew Goldberg, James Hagberg, Kohzo Takebayashi, Mariko Suetsugu, Sadao Wakabayashi, Yoshimasa Aso, Toshihiko Inukai, Hwee Teoh, Fina Lovren, Subodh Verma, Tsutomu Hirano, Toshiyuki Hayashi, Mitsuru Adachi, Takayasu Taira, Hiroaki Hattori, Hilde Marie, Angell Eid, Henrik Reims, Harald Arnesen, Erik Sverre, Torstein Kjeldsen, Ingebjørg Lyberg, Hitomi Nakayama, Shuichi Otabe, Takato Ueno, Naotoshi Hirota, Xiaohong Yuan, Tomoka Fukutani, Toshihiko Hashinaga, Nobuhiko Wada, Kentaro Yamada
Journal: Metabolism (2007)
Consensus Statement: Atlantic Coast Contaminants Workshop 2000
Authors: Sylvain De Guise, Susan D. Shaw, John S. Barclay, John Brock, Abraham Brouwer, Eric Dewailly, Patricia A. Fair, Michel Fournier, Philippe Grandjean, Louis J. Guillette, Mark E. Hahn, Corine Koopman-Esseboom, Robert J. Letcher, Angela Matz, Ross J. Norstrom, Christopher R. Perkins, Lori Schwacke, Janneche Utne Skaare, John Sowles, David J. St. Aubin, John Stegeman, Janet E. Whaley
Journal: Environmental Health Perspectives (2001)
Studies Identify Non-Hodgkin Lymphoma Suppressor
Journal: Cancer Discovery (2015)

Two new studies show that the histone methyltransferase KMT2D, known to be frequently mutated in the two most common forms of non-Hodgkin lymphoma, is a bona fide tumor suppressor. KMT2D mutations are loss-of-function events that remodel the epigenetic landscape of developing B cells, predisposing them toward malignancy.
Not uncommon: HBV genotype g co-infection in HBeAg-negative chronic HBV infected patients
Authors: Michael Basic, Alica Kubesch, Lisa Kuhnhenn, Gert Carra, Johannes Vermehren, Viola Knop, Christiana Graf, Julia Dietz, Stefan Zeuzem, Christoph Sarrazin, Eberhard Hildt, Kai-Henrik Peiffer
Journal: Journal of Hepatology (2020)
Localization of First Lymph Node Metastasis in Breast Carcinoma
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abandonment. 3
Authors: A. R. Holder
Journal: JAMA (1973)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Upregulation of insulin receptor substrate-2 in pancreatic β cells prevents diabetes
Authors: Anita M. Hennige, Deborah J. Burks, Umut Ozcan, Rohit N. Kulkarni, Jing Ye, Sunmin Park, Markus Schubert, Tracey L. Fisher, Matt A. Dow, Rebecca Leshan, Mark Zakaria, Mahmud Mossa-Basha, Morris F. White
Journal: Journal of Clinical Investigation (2003)

The insulin receptor substrate-2 (Irs2) branch of the insulin/IGF signaling system coordinates peripheral insulin action and pancreatic β cell function, so mice lacking Irs2 display similarities to humans with type 2 diabetes. Here we show that β cell–specific expression of Irs2 at a low or a high level delivered a graded physiologic response that promoted β cell growth, survival, and insulin secretion that prevented diabetes in Irs2–/– mice, obese mice, and streptozotocin-treated mice; and that upon transplantation, the transgenic islets cured diabetes more effectively than WT islets. Thus, pharmacological approaches that promote Irs2 expression in β cells, especially specific cAMP agonists, could be rational treatments for β cell failure and diabetes.
Clinical study of ticrynafen. A new diuretic, antihypertensive, and uricosuric agent
Authors: M. Nemati
Journal: JAMA (1977)

In a double-blind study, 20 hypertensive patients were randomly assigned to a six-week regimen of either ticrynafen or hydrochlorothiazide. Blood pressure was significantly reduced with both medications, although most patients required an increase in dosage from 250 to 500 mg ticrynafen daily. Whereas the serum uric acid level rose moderately in the hydrochlorothiazide-treated patients, it fell strikingly to less than half of the pretreatment level in patients treated with ticrynafen. Body weight decreased slightly in both groups, as did serum potassium levels. Blood urea nitrogen and serum creatinine levels rose slightly in both groups. The magnitude of these changes was not significantly different between the two groups. Use of ticrynafen was well tolerated. Ticrynafen appears to be a useful new antihypertensive agent because of its unique combination of diuretic, antihypertensive, and hypouricemic effects. (<i>JAMA</i>237:652-657, 1977)
Public Decency and Public Health
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Genetic Testing
Authors: Wylie Burke
Journal: New England Journal of Medicine (2002)

Classic genetic tests indicate, either directly or indirectly, the presence of DNA variants associated with rare but highly penetrant disorders such as Huntington's disease or multiple endocrine neoplasia type 2. This article not only reviews these classic tests but also shows how novel genetic tests can reveal the presence of DNA variants that are more logically considered risk factors for a given condition.
Fifteenth Annual Report of the State Board of Health of New York.
Journal: JAMA (1896)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A phase II neoadjuvant trial of concurrent trastuzumab and paclitaxel without anthracycline in women with HER2-positive operable breast cancer.
Authors: H. Jinno, T. Hayashida, M. Takahashi, S. Hirose, Y. Kitagawa
Journal: Journal of Clinical Oncology (2011)

283 Background: Neoadjuvant paclitaxel plus trastuzumab followed by 5-fluorouracil, epirubicin, and cyclophosphamide plus trastuzumab revealed the high pathologic complete response (pCR) rate of up to 60% in patients with HER2-positive breast cancer. However, combination of trastuzumab and anthracycline has been associated with an increased incidence of cardiac dysfunction. The objective of this study was to determine the efficacy of concurrent administration of trastuzumab and paclitaxel without anthracycline as neoadjuvant chemotherapy. Predictive factors of pCR including deregulation of the phosphatidylinositol 3-kinase (PI3K) pathway were also investigated. Methods: Patients with HER2-positive operable breast cancer received 12 cycles of weekly paclitaxel (80 mg/m 2 IV) plus weekly trastuzumab (4mg/kg loading dose followed by 2 mg/kg IV) before surgery. PTEN status was evaluated by IHC with PTEN antibody (Thermo Scientific, CA). PTEN expression level was scored semiquantitatively based on staining intensity (0; no staining , 1+; reduced staining, and 2+; equal staining as compared to the internal control). PIK3CA mutation status was evaluated by sequencing of PIK3CA exons 9 and 20 using PCR amplification and direct sequencing. pCR was defined as no residual invasive carcinoma in the breast. Results: Among 37 patients enrolled, ER and PgR were positive in 18 (48.6%) and 16 (43.2%) patients, respectively. The overall response rate was 86.5% (32/37) and the pCR rate was 48.6% (18/37). pCR rate was significantly correlated with PgR negativity (p=0.004) and higher Ki67 (p=0.01). PTEN loss was observed in 33.3% (8/24) of the tumor examined. PIK3CA sequence analysis of the 13 tumors identified 2 mutations in exon 20 and 2 mutations in exon 9, corresponding to a PIK3CA mutation frequency of 30.8%. PTEN loss and/or PIK3CA mutation were not significantly associated with pCR rate. Conclusions: These data indicate that the combination of trastuzumab and paclitaxel without anthracycline is effective neoadjuvant chemotherapy with high pCR rate. PTEN loss and/or PIK3CA mutation were not useful predictors of resistance to trastuzumab.
A1.33 Among human macrophages polarised to different phenotypes, the M-CSF-oriented cells present the highest pro-inflammatory response to the rheumatoid arthritis-specific immune complexes containing ACPA
Authors: C Clavel, L Ceccato, F Anquetil, G Serre, M Sebbag
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background and objectives</h3> In the inflamed synovium of rheumatoid arthritis (RA) patients, autoantibodies to citrullinated proteins (ACPA) probably form immune complexes (IC) on deposits of citrullinated fibrin. We showed that <i><i>in vitro</i></i> such ACPA-IC activate a pro-inflammatory cytokine response in M-CSF-differentiated macrophages. Our objective was to evaluate how macrophage polarisation influences this response. <h3>Methods</h3> CD14-positive monocytes from healthy donors were cultured in the presence of M-CSF, IFN-γ, IL-4 or IL-10. Expression of markers specific for polarised macrophages was analysed by flow cytometry. Their cytokine secretion was prompted by <i><i>in vitro</i></i> generated ACPA-IC, and assayed in the culture supernatants. <h3>Results</h3> IFN-γ-polarised cells exhibited high levels of CD64 and CD80. Low expression of CD14 and high expression of CD206 characterised the IL-4-polarised cells. Exposure to IL-10 or M-CSF raised the expression of CD14, CD32, and CD163. The two cell types lacked CD80 and exhibited similar expression of CD64, CD200R and CD206. In response to ACPA-IC, the secretion of IL-1β, IL-6 and IL-8 was similar among cells exposed to IFN-γ, IL-4 or IL-10. However, the later cells were associated with the highest IL-1Ra:IL-1β and the lowest TNF-α:IL-10 ratios. Conversely, M-CSF-exposed cells secreted the highest levels of pro-inflammatory cytokines, exhibited a high TNF-α:IL-10 and the lowest IL-1Ra:IL-1β ratio. <h3>Conclusions</h3> Despite their phenotypic similarity, IL-10- and M-CSF-polarised macrophages clearly differ in their cytokine response to ACPA-IC. M-CSF-polarised cells exhibit the highest pro-inflammatory potential. Since M-CSF is abundant in the RA synovium, therein it probably drives macrophages towards a strong pro-inflammatory cytokine response to the locally formed ACPA-IC.
Publication of Summary of Notifiable Diseases—United States, 1996
Journal: JAMA (1997)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Hormonal Regulation of Food Intake, Digestion, and Absorption
Authors: C. Nicholl
Journal: Annual Review of Nutrition (1985)

The Hormonal Regulation of Food Intake, Digestion, and Absorption, Page 1 of 1 < Previous page | Next page > /docserver/preview/fulltext/nutr/5/1/annurev.nu.05.070185.001241-1.gif
Some Practical Aspects of Cancer Prevention
Authors: Ernest L. Wynder
Journal: New England Journal of Medicine (1952)

IN 1926 Ewing, in an article on "Cancer Prevention," wrote that "though a great body of clinical information shows that many forms of cancer are due to preventable causes, there has been little systematic research to impress this fact on the medical profession or to convey it to the public."1 This was true then, as it is today, even though the history of environmental cancer, — and thus of cancer prevention, — dates back as far as 1775 to Pott's observation on the high incidence of scrotal cancer among chimney sweeps.2 After Pott's observation many decades passed before further statements . . .
Happenings at a medical school in the late sixties
Authors: R. O. Egeberg
Journal: JAMA (1989)

Indiana's Senator James Watson told me when I was 11 years old that I could grow up to be president of the United States because my father was an immigrant and I was born here. But nobody ever told me I could be dean of a medical school. So I was amazed and honored when Dr Norman Topping, president of the University of Southern California, offered me that position in 1964. I was from the other side of the tracks. I had gone up the clinical ladder, from clinical instructor of medicine to clinical professor, but had never been part of academia. I was going to have to learn, on the job, the delicate difference between administering to a medical faculty's needs and a similar responsibility in a large teaching hospital. I found that generically there was none. But the students were a surprise. I found school-oriented activists urging changes
Social Medicine and Miscellany
Journal: JAMA (1926)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Intravenous glucagon.
Authors: J J Fennelly
Journal: BMJ (1972)

47improvement as demonstrated by reduction or in some cases disappearance of spon- taneous pain in walking (so much so that after many years two patients were able to go upstairs without pause).The rheographic tracing was not modified in one case; in six others it showed an im- provement both in baseline conditions and after trinitrin.More prolonged and extended trial is needed to confirm the preliminary observations.